WO2010109610A1 - Conteneur de composition pharmaceutique - Google Patents

Conteneur de composition pharmaceutique Download PDF

Info

Publication number
WO2010109610A1
WO2010109610A1 PCT/JP2009/055972 JP2009055972W WO2010109610A1 WO 2010109610 A1 WO2010109610 A1 WO 2010109610A1 JP 2009055972 W JP2009055972 W JP 2009055972W WO 2010109610 A1 WO2010109610 A1 WO 2010109610A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
swallowing
container
composition container
storage
Prior art date
Application number
PCT/JP2009/055972
Other languages
English (en)
Japanese (ja)
Inventor
修司 盛本
Original Assignee
株式会社モリモト医薬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社モリモト医薬 filed Critical 株式会社モリモト医薬
Priority to PCT/JP2009/055972 priority Critical patent/WO2010109610A1/fr
Priority to EP10756162.3A priority patent/EP2412357A4/fr
Priority to US13/257,424 priority patent/US20120012480A1/en
Priority to CN2010800119716A priority patent/CN102438575A/zh
Priority to KR1020117024735A priority patent/KR20110131295A/ko
Priority to JP2011506110A priority patent/JPWO2010110366A1/ja
Priority to PCT/JP2010/055212 priority patent/WO2010110366A1/fr
Publication of WO2010109610A1 publication Critical patent/WO2010109610A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0046—Cups, bottles or bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A61J1/2024—Separating means having peelable seals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0053—Syringes, pipettes or oral dispensers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3261—Flexible containers having several compartments
    • B65D81/3266—Flexible containers having several compartments separated by a common rupturable seal, a clip or other removable fastening device

Definitions

  • the present invention relates to a pharmaceutical composition container, and more particularly, to a pharmaceutical composition container capable of reducing the residual amount of the pharmaceutical composition.
  • Patent Document 1 discloses a multi-chamber container.
  • This multi-chamber container partitions a plurality of spaces so as to communicate with each other. These spaces are closed in a state where they can communicate with each other by a force applied from the outside. In any of these spaces, the granular agent is accommodated in a sealed state.
  • the other space contains a dense fluid substance in a sealed state.
  • Each space is communicated with each other, and after the granular material and the concentrated fluid substance are collected and mixed, the mixture can be taken out from a take-out port provided in any one of the spaces.
  • Patent Document 1 when the pharmaceutical composition is a powder, powder or granule, there is a problem that there is a high possibility that they remain in the multi-chamber container.
  • the technical problem of the present invention was made to solve the above problems, and an object of the present invention is to provide a pharmaceutical composition container that can reduce the residual amount of the pharmaceutical composition. .
  • the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 has a plurality of spaces 30, 32, 34, 36, 38, 100, 102,110,112,114,116,150. Between two adjacent spaces 70, 71, 72, 76 are closed. The space 70, 71, 72, 76 between two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18.
  • the swallowing assisting substance 40 is accommodated in the swallowing assisting substance accommodating chambers 30, 100, 102, 104, 106 which are at least one of the spaces.
  • the storages 42 and 120 are stored in the storage chambers 32 and 110, which are at least one of the spaces.
  • the inclusions 42 and 120 contain a pharmaceutical composition 80.
  • the pharmaceutical composition containers 10, 11, 12, 14, 15, 16, 18 are provided with an opening formation scheduled portion 60.
  • the opening formation scheduled portion 60 is a portion where the opening is scheduled to be formed.
  • the opening communicates the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 with the spaces 30, 32, 34, 36, 38, 100, 102, 110, 112, 114, 116, 150.
  • the space 70, 71, 72, 76 between two adjacent spaces opens when a force applied from the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 is applied.
  • the swallowing auxiliary substance 40 is moved from the swallowing auxiliary substance containing chambers 30, 100, 102, 104, 106 to the inclusion holding chambers 32, 110, 112, 114. It becomes possible to guide to.
  • the opening is formed in the opening formation scheduled portion 60, the opening is applied to the mouth of a person who has difficulty in swallowing, and when the swallowing auxiliary substance 40 and the inclusion 42 are pushed out of the opening, the swallowing auxiliary substance 40 is wrapped.
  • the inclusion 42 enters the mouth of a person who is difficult to swallow in a rare state.
  • the inclusion 42 is swallowed. Since the pharmaceutical composition 80 is contained in the storage 42, when the storage 42 is pushed out, the pharmaceutical composition 80 in the storage 42 is also pushed out at the same time. As a result, the residual amount of the pharmaceutical composition 80 in the storage container 32 is lower than when the pharmaceutical composition 80 is not contained in the storage 42.
  • the above-described swallowing auxiliary substance 40 contains water.
  • the material of the inclusion 42 is a water-soluble substance.
  • the above-described swallowing aid substance 40 is a jelly containing moisture.
  • the water-soluble substance is starch.
  • an empty room 116 which is at least one of the above-described spaces, be disposed between the swallowing auxiliary substance storage chamber 102 and the stored material storage chambers 32 and 114.
  • the vacant space 116 is provided, the swallowing aid substance 40 is contained in the inclusion 42 when the two adjacent spaces 102 and 114 communicate with each other against the intention of the user or the handler of the pharmaceutical composition container 15. The possibility of touching is reduced. If the possibility becomes low, the possibility that the encapsulated material 42 will dissolve before taking the pharmaceutical composition 80 also becomes low. As a result, the pharmaceutical composition container 15 is easy to store and easy to handle.
  • the surface of the inclusion 42 described above dissolves in the components of the swallowing auxiliary substance 40.
  • the surface of the inclusion 42 is dissolved with respect to the component of the swallowing auxiliary substance 40, after the swallowing auxiliary substance 40 is guided to the inclusion containing chamber 32, the surface of the inclusion 42 is dissolved. Since the surface is melted while being wrapped in the swallowing auxiliary substance 40, even if it is difficult for the person to swallow, the stored item 42 can be swallowed easily. By swallowing the inclusion 42, the pharmaceutical composition 80 is also swallowed.
  • sealing in the present specification means being closed so that there is no gap.
  • the residual amount of the pharmaceutical composition can be reduced.
  • FIG. 1 is a partially cutaway view of a pharmaceutical composition container 10 according to the present embodiment.
  • FIG. 2 is a diagram illustrating a usage state of the pharmaceutical composition container 10 according to the present embodiment.
  • the pharmaceutical composition container 10 is affixed around the sheets 20 and 20 made of two synthetic resins that are superposed on each other (preferably a soft material that can be folded, such as low-density polyethylene). It is formed by combining.
  • a swallowing auxiliary substance storage chamber 30, a stored material storage chamber 32, and an outlet chamber 34 are formed in the pharmaceutical composition container 10.
  • the swallowing auxiliary substance storage chamber 30, the inclusion storage chamber 32, and the outlet chamber 34 are formed so as to maintain airtightness with respect to the external space.
  • the swallowing auxiliary substance storage chamber 30, the stored item storage chamber 32, and the outlet chamber 34 are arranged in a line.
  • a swallowing assistance substance 40 is housed in the swallowing assistance substance accommodation chamber 30.
  • the swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing water.
  • the moisture content of the jelly is set so as to ensure at least 2 minutes from when the swallowing auxiliary substance 40 covers the surface of the inclusion 42 described later until the inclusion 42 is completely dissolved.
  • the exit chamber 34 in this embodiment is an empty room.
  • a storage 42 made of oblate is stored in the storage room 32.
  • a granulated drug or other pharmaceutical composition 80 is accommodated in the inclusion 42.
  • the inclusion 42 according to the present embodiment is obtained by putting the pharmaceutical composition 80 in a commercially available wafer and twisting a portion corresponding to the entrance of the pharmaceutical composition 80. Thereby, the stored item 42 is sealed.
  • a starch wafer having a thickness of 10 ⁇ m is used. This is used in order to secure at least 2 minutes from when the swallowing auxiliary substance 40 covers the surface of the storage 42 until the storage 42 is completely dissolved.
  • the thickness of the wafer should be appropriately selected according to the material.
  • a gas for example, nitrogen gas
  • nitrogen gas that does not affect the pharmaceutical composition 80 and the swallowing auxiliary substance 40 is sealed in the storage container 32 and the swallowing auxiliary substance holding room 30 as necessary.
  • the swallowing auxiliary substance storage chamber 30 and the stored material storage chamber 32 are partitioned by a first weak seal portion 70.
  • the inclusion storage chamber 32 and the outlet chamber 34 are partitioned by a second weak seal portion 72.
  • the first weak seal portion 70 and the second weak seal portion 72 are portions between two adjacent spaces among the bonded portions of the two sheets 20 and 20.
  • the strength of the first weak seal portion 70 and the second weak seal portion 72 is such that the outer peripheral strong seal portion 74 (the first weak seal portion 70 and the second weak seal among the portions where the two sheets 20 and 20 are bonded together). It is lower than the strength of the portion other than the seal portion 72). This can be achieved by using different materials for the adhesive when the two sheets 20 and 20 are bonded together.
  • the swallowing auxiliary substance storage chamber 30 when the first weak seal portion 70 and the second weak seal portion 72 are pushed from the outside of the pharmaceutical composition container 10 when the swallowing auxiliary substance storage chamber 30 or the inclusion storage chamber 32 is pushed out of the pharmaceutical composition container 10, the swallowing auxiliary substance storage chamber 30. Or it peels easily with the force which the swallowing auxiliary
  • a pair of cut portions 50 each having a V-shaped cut are formed on both sides of the exit chamber 34.
  • the opening formation scheduled portion 60 sandwiched between the cut portions 50 is a portion where the opening is scheduled to be formed. This opening allows the outside and the inside of the outlet chamber 34 to communicate with each other.
  • a caregiver or the like pushes the swallowing auxiliary substance storage chamber 30 from the outside of the pharmaceutical composition container 10 and peels the first weak seal portion 70 by pressure from the inside of the swallowing auxiliary substance storage chamber 30.
  • the swallowing auxiliary substance 40 is pushed out into the storage container chamber 32.
  • the pushed swallowing auxiliary substance 40 spreads in the storage container chamber 32 and fills the periphery of the storage object 42. From this time, the surface of the inclusion 42 starts to melt by the swallowing aid 40.
  • the swallowing auxiliary substance 40 After the swallowing auxiliary substance 40 is pushed out into the storage container chamber 32, a caregiver, a patient 90, or the like squeezes the pharmaceutical composition container 10 in the direction from the swallowing auxiliary substance storage chamber 30 toward the storage container chamber 32. Thereby, as a result of the pressure being applied to the swallowing auxiliary substance 40, the second weak seal portion 72 is peeled off. When the second weak seal portion 72 is peeled off, the swallowing auxiliary substance 40 and the inclusion 42 are pushed out to the outlet chamber 34. When the swallowing auxiliary substance 40 and the inclusion 42 are pushed out to the outlet chamber 34, a caregiver, a patient 90, or the like applies a shearing force to the incision portion 50 to provide an opening in the outlet chamber 34.
  • FIG. 2 shows a situation where the patient 90 is squeezing the pharmaceutical composition container 10.
  • the surface of the inclusion 42 is dissolved in the component of the swallowing auxiliary substance 40, the surface of the inclusion 42 is easily slipped. Since the surface of the inclusion 42 is easy to slide, the inclusion 42 is swallowed smoothly.
  • the pharmaceutical composition container 10 has the following effects.
  • the first effect is that the granular drug or other pharmaceutical composition 80 can be swallowed easily.
  • the second effect is that the taste such as the bitterness of the drug is suppressed.
  • the third effect is an effect that the pharmaceutical composition 80 can be prevented from being scattered in the mouth.
  • the fourth effect is that there is no need to worry about the stability of the drug.
  • the fifth effect is an effect that various kinds of solids can be taken by a person who has difficulty in swallowing.
  • the sixth effect is that the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 10 can be reduced (in the case of the present embodiment, the residual amount can be made an amount close to zero). .
  • the inclusion 42 enters the mouth of the patient 90 in a state of being wrapped in the swallowing auxiliary substance 40. At this time, the surface of the inclusion 42 is melted. Since the surface is melted while being wrapped in the swallowing assisting material 40, even the patient 90 who is difficult to swallow can easily swallow the stored matter 42. Since the encapsulated product 42 contains the pharmaceutical composition 80, the medicinal composition 80 is also swallowed by swallowing the encapsulated product 42. Thereby, the pharmaceutical composition 80 can be swallowed easily.
  • the inclusion 42 enters the mouth of the patient 90 in a state of being wrapped in the swallowing auxiliary substance 40.
  • the pharmaceutical composition 80 which is the content of the stored product 42 is double-wrapped by the swallowing auxiliary substance 40 and the stored product 42. Since the pharmaceutical composition 80 is wrapped in a double layer, even if the pharmaceutical composition 80 is a drug, the possibility that the tongue of the patient 90 senses its taste such as bitterness is low. As a result, the taste such as the bitterness of the drug is suppressed.
  • the pharmaceutical composition 80 is double-wrapped by the swallowing auxiliary substance 40 and the inclusion 42. Thereby, the possibility that the pharmaceutical composition 80 is scattered in the mouth of the patient 90 is reduced. As a result, scattering of the pharmaceutical composition 80 in the mouth can be suppressed.
  • the drug is a chemical substance. When chemical substances come into contact, chemical reactions often occur. Due to the chemical reaction, the drug loses its medicinal properties. For this reason, in many cases, a plurality of drugs cannot be stored in a mixed state. When storing them in a mixed state, it is necessary to check in advance whether their medicinal properties are lost.
  • the pharmaceutical composition container 10 according to the present embodiment is provided with a plurality of spaces. Storing one type of drug in each space and storing a plurality of drugs separately are substantially the same. This is the reason why it is not necessary to worry about the stability of the drug if the pharmaceutical composition container 10 according to this embodiment is used. Since there is no need to worry about the stability of the drugs, there is no need to examine in advance whether the efficacy of a plurality of drugs has been lost.
  • the fifth effect will be described. After the swallowing assisting substance 40 is guided to the storage container chamber 32, the swallowing assisting substance 40 and the storing object 42 are swallowed, so that the activity of the pharmaceutical composition 80 itself does not have a great influence on the difficulty of swallowing. Thereby, various kinds of solids can be taken for those who have difficulty in swallowing.
  • the container 42 according to the present embodiment is sealed. Since it is sealed, the possibility of the pharmaceutical composition 80 leaking out of the inclusion 42 is very low. Since the possibility is extremely low, the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 10 can be reduced (actually, the residual amount is made close to zero).
  • the pharmaceutical composition container 10 described in the present embodiment is illustrated to embody the technical idea of the present invention. This does not limit the material of the sheet 20 to the above-described embodiment. This does not limit the shape of the sheet 20, the shape of each space, the shape of the opening, their dimensions, their structure, their arrangement, and the like to the above-described embodiment.
  • the pharmaceutical composition container 10 described in the present embodiment can be variously modified within the scope of the technical idea of the present invention.
  • FIG. 3 is a partially cutaway view of the pharmaceutical composition container 12 according to the first modification.
  • the first tapered portion 130 of the swallowing auxiliary substance storage chamber 100 that faces the storage container 110 is gradually narrowed toward the storage container 110.
  • the 2nd taper part 140 which opposes the swallowing auxiliary substance storage chamber 100 among the inclusion storage rooms 110 is gradually narrowed toward the swallowing auxiliary substance storage chamber 100.
  • a bag-like inclusion 120 as shown in FIG. 3 may be accommodated.
  • the stored item 120 may be accommodated in the pharmaceutical composition container 10 shown in FIG.
  • the shape of the inclusion is not limited to that shown in FIGS.
  • the swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing moisture.
  • the surface of the capsule melt
  • the capsule dissolves in the digestive juice inside the stomach and intestines.
  • FIG. 4 is a partially cutaway view of the pharmaceutical composition container 14 according to the second modification.
  • a swallowing auxiliary substance storage chamber 102, a first storage container storage chamber 112, a second storage container storage chamber 114, and an outlet chamber 150 are formed in the pharmaceutical composition container 14.
  • the swallowing auxiliary substance storage chamber 102, the first storage container storage chamber 112, the second storage container storage chamber 114, and the outlet chamber 150 are arranged in a line. Note that the end of the first storage container chamber 112 on the second storage container chamber 114 side becomes narrower as it approaches the second storage container chamber 114 and is stored in the first storage container chamber 112.
  • the object 42 Since the object 42 is accommodated, when the inclusion 42 is pushed out by the swallowing auxiliary substance 40, it can be smoothly performed. Since the end of the second storage chamber 114 on the outlet chamber 150 side becomes narrower as it approaches the outlet chamber 150, and the storage 42 is stored in the second storage chamber 114, this end The inclusion 42 is also pushed out with the same smoothness.
  • a bag-shaped storage 120 instead of storing the storage 42 in the first storage chamber 112 and the second storage chamber 114, a bag-shaped storage 120 as shown in FIG. 3 may be stored.
  • FIG. 5 is a partially cutaway view of a pharmaceutical composition container 15 according to a third modification.
  • a vacant chamber 116 is provided instead of the first storage container chamber 112 shown in FIG. If the vacant chamber 116 is provided, the possibility of mixing the swallowing aid substance 40 and the pharmaceutical composition 80 can be reduced to some extent even if the sealing performance between the spaces is impaired due to an accident. If the pharmaceutical composition container 15 can be bent at the portion of the empty space 116, the possibility of mixing the swallowing aid substance 40 and the pharmaceutical composition 80 can be further reduced by bending that portion.
  • the pharmaceutical composition container is not limited to a laminate of two sheets.
  • FIG. 6 is a partially cutaway view of the pharmaceutical composition container 16 according to the fourth modification.
  • FIG. 7 is a partially cutaway view of a pharmaceutical composition container 18 according to a fifth modification. These are formed by folding one sheet in half.
  • the pharmaceutical composition containers 16 and 18 are formed by folding one sheet in half, the swallowing assistance substance containing chamber 104, compared to the pharmaceutical composition container formed by bonding two sheets with the same outer diameter.
  • the volume of 106 can be increased.
  • the pharmaceutical composition container may be obtained by pasting together portions of one tube.
  • the cut portion 50 is configured with a V-shaped cut, but the cut portion of the present invention may have a shape other than the V shape.
  • the pharmaceutical composition is a powder or a granule and the swallowing auxiliary substance is jelly has been described, but the pharmaceutical composition and the swallowing auxiliary substance applied to the present invention are not limited thereto.
  • the pharmaceutical composition may be a tablet, a capsule or a simple lump in addition to a powder or a granule.
  • the swallowing aid may be honey, custard cream, peanut spread, cheese spread, etc. in addition to the aqueous solution.
  • molded as a pharmaceutical composition is not limited to the thing normally handled as a pharmaceutical.
  • the product molded as a pharmaceutical composition may be a food that has been recognized to improve health.
  • materials for the inclusions various materials conventionally used as materials for edible films can be used in addition to the above-mentioned 10 ⁇ m thick starch oblate. These materials include polysaccharides (eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.) and peptide substances (eg, gelatin, silk protein degradation products, casein) Decomposition products). These materials can be used alone or in combination of two or more.
  • polysaccharides eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.
  • peptide substances eg, gelatin, silk protein degradation products, casein
  • the outlet chambers 34 and 150 are described. However, the outlet chamber 34 is not provided, and the notch 50 is provided in the storage chamber 32 or the like. An opening may be provided by applying a shearing force to the portion 50, and the opening may be applied to the patient's mouth.
  • the structure of 70, 71, 72 between two adjacent spaces may be different from that described above.
  • a thin film may be formed between two adjacent spaces 70, 71, 72.
  • Such a film can be formed by sandwiching a member to be a film between two sheets 20 and 20 and bonding them together.
  • the structure of 70, 71, 72 between two adjacent spaces must be a structure that is closed in a state where they can communicate with each other by a force applied from the outside of the pharmaceutical composition container 10.
  • This “force applied from the outside of the pharmaceutical composition container 10” may be a force directly applied to 70, 71, 72 between two adjacent spaces, or a force indirectly applied to one of them. There may be.
  • FIG. 8 is a partially cutaway view of the pharmaceutical composition container 11 according to the sixth modification.
  • a first bag storage chamber 36, a second bag storage chamber 38, a stored item storage chamber 32, and an outlet chamber 34 are formed. Similar to the container storage chamber 32 and the outlet chamber 34, the first bag storage chamber 36 and the second bag storage chamber 38 are also formed so as to be airtight with respect to the external space.
  • the first bag storage chamber 36 and the second bag storage chamber 38 store the auxiliary substance storage bag 22 and fix it. It is the outer peripheral strong seal portion 74 and the third weak seal portion 76 that directly fix the auxiliary substance containing bag 22.
  • the strength of the third weak seal portion 76 against peeling is substantially the same as that of the outer peripheral strong seal portion 74.
  • the auxiliary substance storage bag 22 stores the swallowing auxiliary substance 40.
  • the strength of one end of the auxiliary substance storage bag 22 facing the first weak seal portion 70 is a strength that is broken by a force applied from the outside of the pharmaceutical composition container 11.
  • the swallowing auxiliary substance 40 is sterilized together with the auxiliary substance containing bag 22, and is then sandwiched between the sheets 20 and 20 and adhered thereto. Thereafter, the outer peripheral strong seal portion 74 and the like are formed. Thereby, when force is applied from the outside of the pharmaceutical composition container 11, one end of the auxiliary substance storage bag 22 is peeled off. When it is peeled off, the swallowing auxiliary substance 40 leaks into the first bag storage chamber 36.
  • the first weak seal portion 70 is peeled by the force received from the swallowing auxiliary substance 40.
  • the inclusion 42 is wrapped in the swallowing aid substance 40.
  • the pharmaceutical composition container according to the present invention can be suitably used as a container for taking medicine.
  • the container for taking medicine can be suitably used for a medicine filled by the following system.
  • the system is a system in which a plurality of auger filling machines are installed, a transport system and a weighing system are added, and connected to a pharmaceutical production line to perform automatic operation for a long time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mechanical Engineering (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un conteneur de composition pharmaceutique qui peut être facilement avalé sans que la composition pharmaceutique ne se répande dans la bouche, et dans lequel la composition pharmaceutique peut être aisément chargée. L'invention concerne ainsi un conteneur de composition pharmaceutique (10) qui comprend une pluralité d'espaces (30, 32, 50). Les parties (70, 72) situées entre deux espaces adjacents sont fermées et ne s'ouvrent que lorsqu'on exerce sur elles une force depuis l'extérieur du conteneur (10). Une substance facilitant la déglutition (40) est contenue dans un compartiment (30) correspondant. De même, une matière d'encapsulation (42) est contenue dans un compartiment (32) correspondant. La matière d'encapsulation (42) renferme une composition pharmaceutique (80) donnée. Par ailleurs, une feuille (20) comprend une partie (60) dans laquelle une ouverture doit être créée. Cette ouverture relie l'extérieur du conteneur de composition pharmaceutique (10) aux différents espaces (30, 32, 50).
PCT/JP2009/055972 2009-03-25 2009-03-25 Conteneur de composition pharmaceutique WO2010109610A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PCT/JP2009/055972 WO2010109610A1 (fr) 2009-03-25 2009-03-25 Conteneur de composition pharmaceutique
EP10756162.3A EP2412357A4 (fr) 2009-03-25 2010-03-25 Conditionnement de composition médicinale
US13/257,424 US20120012480A1 (en) 2009-03-25 2010-03-25 Pharmaceutical composition container
CN2010800119716A CN102438575A (zh) 2009-03-25 2010-03-25 医药组成物容器
KR1020117024735A KR20110131295A (ko) 2009-03-25 2010-03-25 의약조성물 용기
JP2011506110A JPWO2010110366A1 (ja) 2009-03-25 2010-03-25 医薬組成物容器
PCT/JP2010/055212 WO2010110366A1 (fr) 2009-03-25 2010-03-25 Conditionnement de composition médicinale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2009/055972 WO2010109610A1 (fr) 2009-03-25 2009-03-25 Conteneur de composition pharmaceutique

Publications (1)

Publication Number Publication Date
WO2010109610A1 true WO2010109610A1 (fr) 2010-09-30

Family

ID=42780319

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2009/055972 WO2010109610A1 (fr) 2009-03-25 2009-03-25 Conteneur de composition pharmaceutique
PCT/JP2010/055212 WO2010110366A1 (fr) 2009-03-25 2010-03-25 Conditionnement de composition médicinale

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/055212 WO2010110366A1 (fr) 2009-03-25 2010-03-25 Conditionnement de composition médicinale

Country Status (6)

Country Link
US (1) US20120012480A1 (fr)
EP (1) EP2412357A4 (fr)
JP (1) JPWO2010110366A1 (fr)
KR (1) KR20110131295A (fr)
CN (1) CN102438575A (fr)
WO (2) WO2010109610A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105722492B (zh) * 2013-10-29 2019-12-27 株式会社盛本医药 分包体、分包体的制造方法以及分包体的制造装置
WO2015114749A1 (fr) * 2014-01-29 2015-08-06 株式会社モリモト医薬 Cellule contenant un médicament oral, emballage en chapelets, et procédé de fabrication de cellules contenant un médicament oral
JP6514547B2 (ja) * 2015-03-31 2019-05-15 株式会社Uacj 二重包装体
GB2542630A (en) * 2015-09-28 2017-03-29 Medimauve Ltd Sachet system
US20220133596A1 (en) * 2020-11-05 2022-05-05 Purosil LLC Device and method for assisting pill swallowing

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10234820A (ja) * 1996-12-25 1998-09-08 Takeda Chem Ind Ltd 濃厚流動物質を併用する粉粒状剤及びこれらの複室型容器
JPH10291538A (ja) * 1997-04-17 1998-11-04 Material Eng Tech Lab Inc 薬剤入り容器
JP2000262589A (ja) * 1999-03-16 2000-09-26 Jms Co Ltd 複室容器
JP2007289402A (ja) * 2006-04-25 2007-11-08 Takamichi Mukoda 散剤及び内用液剤混合袋

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3070094A (en) * 1959-02-25 1962-12-25 Stanley J Sarnoff Medicament and diluent storing, mixing, and dispensing device
US3478871A (en) * 1968-04-29 1969-11-18 Kleer Vu Ind Inc Burst package with fold seal
US3749620A (en) * 1969-11-20 1973-07-31 American Cyanamid Co Package for plural reactable components with rupturable ultrasonic seal
US4402402A (en) * 1981-10-14 1983-09-06 Pike Brian R Barrier seal multiple-compartment package
US4534509A (en) * 1982-09-28 1985-08-13 Firmenich Sa Multiple compartment plastic packing
GB8911878D0 (en) * 1989-05-24 1989-07-12 Allen Nicholas J Mixing device
US5616337A (en) * 1995-01-30 1997-04-01 Genta Incorporated Unit dose skin care package
US5944709A (en) * 1996-05-13 1999-08-31 B. Braun Medical, Inc. Flexible, multiple-compartment drug container and method of making and using same
JPH11313871A (ja) * 1998-05-01 1999-11-16 Hoechst Marion Roussel Kk 輸液容器
DE10056212B4 (de) * 2000-11-13 2005-08-18 3M Espe Ag Vorrichtung zum Lagern und Ausbringen von fließfähigen Zusammensetzungen, Verfahren zur Herstellung und Verwendung der Vorrichtung
JP2002262589A (ja) * 2001-03-01 2002-09-13 Toto Ltd モータ制御装置
JP4312423B2 (ja) * 2002-06-14 2009-08-12 ピジョン株式会社 腸溶性カプセル剤
DE10243401B4 (de) * 2002-09-18 2004-07-29 Voco Gmbh Verpackung zum Lagern von Substanzen und Verfahren zum Herstellen eines direkt applizierbaren Gemisches zweier Substanzen aus dieser Verpackung
JP4027390B2 (ja) * 2002-11-02 2007-12-26 ケッテンバッハ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 粘性の物質の貯蔵及び供給のための装置
JP4679838B2 (ja) * 2004-06-02 2011-05-11 株式会社細川洋行 医療用薬液容器
US7357248B2 (en) * 2004-12-14 2008-04-15 Illinois Tool Works Inc. Point of use cleaning solution
JP4656302B2 (ja) * 2005-03-25 2011-03-23 藤森工業株式会社 複室容器
JP5061897B2 (ja) * 2005-06-06 2012-10-31 味の素株式会社 カプセル皮膜用組成物
EP1963201A2 (fr) * 2005-11-29 2008-09-03 Baxter International Inc. Contenant souple de doses unitaires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10234820A (ja) * 1996-12-25 1998-09-08 Takeda Chem Ind Ltd 濃厚流動物質を併用する粉粒状剤及びこれらの複室型容器
JPH10291538A (ja) * 1997-04-17 1998-11-04 Material Eng Tech Lab Inc 薬剤入り容器
JP2000262589A (ja) * 1999-03-16 2000-09-26 Jms Co Ltd 複室容器
JP2007289402A (ja) * 2006-04-25 2007-11-08 Takamichi Mukoda 散剤及び内用液剤混合袋

Also Published As

Publication number Publication date
EP2412357A1 (fr) 2012-02-01
WO2010110366A1 (fr) 2010-09-30
CN102438575A (zh) 2012-05-02
KR20110131295A (ko) 2011-12-06
US20120012480A1 (en) 2012-01-19
EP2412357A4 (fr) 2014-10-29
JPWO2010110366A1 (ja) 2012-10-04

Similar Documents

Publication Publication Date Title
JP2828505B2 (ja) フレキシブル容器及びその形成方法
WO2010109610A1 (fr) Conteneur de composition pharmaceutique
TW200911643A (en) Multi-compartment package
EP2702976B1 (fr) Récipient pour l'administration d'un médicament
KR101360596B1 (ko) 약액을 수용하는 다구획 용기
WO2010010866A1 (fr) Contenant à médicament
JPH10234820A (ja) 濃厚流動物質を併用する粉粒状剤及びこれらの複室型容器
JP2003062038A (ja) 薬液収容小袋付き薬液容器
JP2994417B2 (ja) 薬剤入り容器
WO2010109612A1 (fr) Conteneur de composition médicale
JP4822860B2 (ja) 医療用複室容器
JP5792939B2 (ja) 医薬組成物容器
JP5588967B2 (ja) 医薬組成物容器
WO2011027795A1 (fr) Préparation pour administration orale
WO2010109611A1 (fr) Conteneur de composition pharmaceutique
US20240351768A1 (en) Double formulation packaging pouch with easy-opening and easy-liquid drinking features
JP3855708B2 (ja) 容器
JP5873483B2 (ja) 投薬用容器
WO2014064840A1 (fr) Dispositif pour l'administration orale de médicament
JP2024155767A (ja) 開封が便利で液状の飲用が容易な二重剤形包装ポーチ
JP2003292055A (ja) 容 器
JP2011147659A (ja) 嚥下用容器
JP2007105181A (ja) 医療用複室容器

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09842224

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09842224

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP